Page last updated: 2024-11-05

troglitazone and Cataract

troglitazone has been researched along with Cataract in 2 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Cataract: Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)

Research Excerpts

ExcerptRelevanceReference
"Troglitazone is a new antidiabetic drug with a combined chemical structure of thiazolidinedione and alpha-tocopherol like structure (chroman ring)."5.30Inhibition of galactose-induced cataractogenesis by troglitazone, a new antidiabetic drug with an antioxidant property, in rat lens culture. ( Horikoshi, H; Inoue, T; Yokoyama, T; Yoshida, Y, 1999)
"Troglitazone was less effective in controlling serum cholesterol and neuropathy."1.31Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. ( Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F, 2000)
"Troglitazone is a new antidiabetic drug with a combined chemical structure of thiazolidinedione and alpha-tocopherol like structure (chroman ring)."1.30Inhibition of galactose-induced cataractogenesis by troglitazone, a new antidiabetic drug with an antioxidant property, in rat lens culture. ( Horikoshi, H; Inoue, T; Yokoyama, T; Yoshida, Y, 1999)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yokoyama, T1
Yoshida, Y1
Inoue, T1
Horikoshi, H1
Shibata, T1
Takeuchi, S1
Yokota, S1
Kakimoto, K1
Yonemori, F1
Wakitani, K1

Other Studies

2 other studies available for troglitazone and Cataract

ArticleYear
Inhibition of galactose-induced cataractogenesis by troglitazone, a new antidiabetic drug with an antioxidant property, in rat lens culture.
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 1999, Volume: 15, Issue:1

    Topics: Aldehyde Reductase; Animals; Antioxidants; Cataract; Chromans; Galactitol; Galactose; Glutathione Pe

1999
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
    British journal of pharmacology, 2000, Volume: 130, Issue:3

    Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chro

2000